Format

Send to

Choose Destination
Onco Targets Ther. 2014 Oct 30;7:2013-9. doi: 10.2147/OTT.S67556. eCollection 2014.

The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells.

Author information

1
Department of Anatomy, Basic Medical College, Zhengzhou University, Henan, People's Republic of China.
2
Department of Pathology, Children's Hospital of Zhengzhou City, Henan, People's Republic of China.
3
Department of Physiology, Basic Medical College, Zhengzhou University, Henan, People's Republic of China.
4
Department of Laboratory, The First Affiliated Hospital of Zhengzhou University, Henan, People's Republic of China.
5
Department of Pharmacy, Zhengzhou Central Hospital, Zhengzhou University, Henan, People's Republic of China.
6
Department of Pathology, Henan Provincial People's Hospital, Henan, People's Republic of China.

Abstract

Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells.

KEYWORDS:

cancer therapy; glioblastoma multiforme; glioma

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center